First Author: N.Unlu TURKEY
Co Author(s): G. Uney M.A. Acar D. Hazirolan F. Ornek 0 0 0 0 0 0 0 0 0
Back to previous
To identify the correlation of central macular thickness with visual outcome in patients with diabetic macular edema (DME) treated with ranibizumab.
Department of Ophthalmology, Ankara Education and Research Hospital
Eighty-two eyes with DME treated with ranibizumab were retrospectively reviewed. All underwent best-corrected visual acuity (BCVA) assessment and optical coherence tomography (OCT) at baseline, 3, 6 and 12 months. Patients were grouped according to the baseline central macular thickness (CMT) into2 groups. Group 1 had CMT <400µm (n=35), Group 2 CMT ≥400 µm (n=42).
At baseline mean visual acuity was 0,63±0.46 logMAR in group 1 and 0.72±0.39 logMAR in group 2. (p=0,199 Mann Whitney U) The BCVA was 0.37±0.45 logMAR in group 1 and 0.61±0.46 logMAR in group 2 (p<0.01) at twelveth month under ranibizumab treatment. Group 1 had a decrease in CMT by 17.9% compared with baseline and group 2 had 30.1%. Thirty eyes (85.75%) had BCVA ≥20/100 in group 1 compared with 35 (74.5%) in group 2. (p=0.104). The visual acuity was improved in 74.3% of eyes in group 1 and 54.7% of eyes in group 2, whereas visual acuity was unchanged in 22.9% and 25.5% respectively in groups.
Ranibizumab was effective in improving and maintaining BCVA and CMT outcomes. Visual acuity improvement was less in cases with a thicker baseline CMT on OCT.